Meta Platforms
META
Petroleo Brasileiro SA Petrobras
PBR
Ecopetrol
EC
Vale SA
VALE
Alphabet-A
GOOGL
US Stock MarketDetailed Quotes
TAK Takeda Pharmaceutical
- 13.085
- -0.155-1.17%
Trading Jan 10 11:27 ET
41.63BMarket Cap22.76P/E (TTM)
13.125High13.020Low772.47KVolume13.050Open13.240Pre Close10.10MTurnover0.03%Turnover Ratio45.43P/E (Static)3.18BShares14.74252wk High0.95P/B40.31BFloat Cap12.29352wk Low0.63Dividend TTM3.08BShs Float19.900Historical High4.83%Div YieldTTM0.79%Amplitude11.308Historical Low13.077Avg Price1Lot Size
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Company Profile
SymbolTAK
Company NameTakeda Pharmaceutical
Listing DateDec 24, 2018
Founded1781
CEOMr. Christophe Weber
MarketNYSE
Employees49281
Securities TypeDR
ADS Ratio2.0 : 1.0
Fiscal Year Ends03-31
Address4-1-1 Dosho-machi,Chuo-Ku
CityOsaka
ProvinceOsaka
CountryJapan
Zip Code540-8645
Phone81-6-6204-2111
Websitehttp://www.takeda.com
Company Executives
- Name
- Position
- Salary
- Akiko Amakawa
- Corporate Strategy Officer and Chief Executive Officer Chief of Staff
- --
- Christophe Weber
- Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.a., Inc.
- 1.70B
- Milano Furuta
- Director and Chief Financial Officer
- --
- Lauren Duprey
- Chief Human Resources Officer
- --
- Gabriele Ricci
- Chief Data and Technology Officer
- --
- Mwana Lugogo
- Chief Ethics and Compliance Officer
- --
- Takako Ohyabu
- Chief Global Corporate Affairs and Sustainability Officer
- --
- Dr. Thomas Wozniewski, PhD
- Global Manufacturing and Supply Officer
- --
- Marcello Agosti
- Global Business Development Officer
- --
- Elaine Shannon
- Global Quality Officer
- --
- Ramona Sequeira
- President, Global Portfolio Division
- --
- Julie Kim
- President, U.S. Business Unit and U.S. Country Head
- --
- Masami Iijima
- Chairman of the Board
- 43.00M
- Giles Platford
- President, Plasma-Derived Therapies Business Unit
- --
- Asuka Miyabashira
- President, Japan Pharma Business Unit
- --
- Andrew S. Plump, M.D.
- Director and President, Research and Development
- 12.00M
- Teresa Marie Bitetti
- President, Global Oncology Business Unit
- --
- Michel Orsinger
- Independent Director
- 46.00M
- Jean-Luc Butel
- Independent Director
- 38.00M
- Koji Hatsukawa
- Independent Director
- 43.00M
- Dr. John M. Maraganore,PhD
- Independent Director
- 39.00M
- Kimberly A. Reed
- Independent Director
- 41.00M
- Dr. Steven Gillis, Pd.D
- Independent Director
- 44.00M
- Miki Tsusaka
- Independent Director
- 32.00M
- Emiko Higashi
- Independent Director
- 49.00M
- Ian T. Clark
- Independent Director
- 44.00M
- Yoshiaki Fujimori
- Independent Director
- 40.00M
- Yoshihiro Nakagawa
- Global General Counsel
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
